Market Impact of Generic and Biosimilar Drugs

State Policy Seminar: Levers to Address Health Costs
June 6, 2022
TRIVIA!!!!
1. What is a biologic?

A. A drug derived from living cells whose structures are complex and characteristics differ.

B. A small molecule drug synthesized from chemical compounds.

C. All drugs are biologics.
1. What is a biologic?

A. A drug derived from living cells whose structures are complex and characteristics differ.

B. A small molecule drug synthesized from chemical compounds.

C. All drugs are biologics.
2. Which group of products are biologics?

A. Over-the-counter drugs.

B. Insulin, vaccines and gene therapies.

C. Drugs used to treat high cholesterol, high blood pressure and antibiotics.
2. Which group of products are biologics?

A. Over-the-counter drugs.

B. Insulin, vaccines and gene therapies.

C. Drugs used to treat high cholesterol, high blood pressure and antibiotics.
3. What is a biosimilar?

A. A drug that is identical to the reference biologic.

B. A drug that bears no resemblance to the reference biologic.

C. A drug that is highly similar to the reference biologic.
3. What is a biosimilar?

A. A drug that is identical to the reference biologic.

B. A drug that bears no resemblance to the reference biologic.

C. A drug considered highly similar to the reference biologic.
4. Which of these statements is true about biosimilars?

A. They are as safe and effective as the reference biologic.

B. They are more expensive than the reference biologic.

C. Biosimilars are sketchy and shouldn’t be trusted.
4. Which of these statements is true about biosimilars?

   A. They are as safe and effective as the reference biologic.

   B. They are more expensive than the reference biologic.

   C. Biosimilars are sketchy and shouldn’t be trusted.
5. A What percentage of prescribed drugs are generics?

A. 50%
B. 90%
C. 3%
5. A What percentage of prescribed drugs are generics?

A. 50%

B. 90%

C. 3%
6. According to the FDA, how much cheaper are the list prices of biosimilar drugs compared to their reference products?

A. 15-35%

B. 95%

C. They are not cheaper. In fact, they are more expensive.
6. According to the FDA, how much cheaper are the list prices of biosimilar drugs compared to their reference products?

A. 15-35%

B. 95%

C. They are not cheaper. In fact, they are more expensive.
7. In 2020, how much money was saved by consumers through the use of generics and biosimilars?

A. $338 billion

B. $338 million

C. $338
7. In 2020, how much money was saved by consumers through the use of generics and biosimilars?

A. $338 billion

B. $338 million

C. $338
8. How many biosimilars are approved by the FDA?

A. 14

B. 100

C. 35
8. How many biosimilars are approved by the FDA?

A. 14

B. 100

C. 35
9. Of those, how many biosimilars have been launched in the U.S. and are available to patients?

A. 35  
B. 21  
C. 0
9. Of those, how many have been launched in the U.S. and are available to patients?

A. 35

B. 21

C. 0
10. What does it mean when a biosimilar is deemed interchangeable by the FDA?

A. A pharmacist can substitute a biosimilar in place of its reference product without first obtaining permission from the prescriber.

B. A pharmacist can substitute a biosimilar but only after obtaining permission from a prescriber.

C. There is no such designation.
10. What does it mean when a biosimilar is deemed interchangeable by the FDA?

A. A pharmacist can substitute a biosimilar in place of its reference product without first obtaining permission from the prescriber.

B. A pharmacist can substitute a biosimilar but only after obtaining permission from a prescriber.

C. There is no such designation.
11. How many interchangeable biosimilars are approved by the FDA?

A. 21

B. 10

C. 2
11. How many interchangeable biosimilars are approved by the FDA?

A. 21

B. 10

C. 2
12. How many states have generic drug substitution laws?

A. All 50 states and D.C.

B. 25

C. 9
12. How many states have generic drug substitution laws?

A. All 50 states and D.C.

B. 25

C. 9
13. How many of those laws address biosimilars?

A. All 50 states and D.C.

B. 25

C. 9
13. How many of those laws address biosimilars?

A. All 50 states and D.C.

B. 25

C. 9